← FDA Drug Approvals (Drugs@FDA)

DIFLUPREDNATE

ANDA · Abbreviated New Drug Application (Generic) · Sponsor: CAPLIN · Approved 2024-12-13

Drug application

FDA Application #

ANDA219441

Application type

Abbreviated New Drug Application (Generic)

Brand name

DIFLUPREDNATE

Generic name

DIFLUPREDNATE

Active ingredients

DIFLUPREDNATE

Dosage form

EMULSION

Route

OPHTHALMIC

Marketing status

Prescription

Sponsor

CAPLIN

Manufacturer

Caplin Steriles Limited

First approval

2024-12-13

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown